The biopharmaceutical company has provided $40m in seed capital for the newly launched immuno-oncology drug developer.
US-based oncology therapy developer Bicara Therapeutics publicly launched yesterday with $40m of seed funding from biopharmaceutical company Biocon.
Bicara is working on bifunctional antibodies intended to treat cancer by delivering immunomodulatory payloads to the tumour microenvironment in order to increase the activity of immune cells.
The startup’s lead product candidate, BCA101, is being studied as a potential single and combination drug and entered phase 1/2 clinical trials in July 2020. It also has a research hub in India supported by…
